A Multi-center, Randomized, Double-blind, Placebo and Active-controlled Study With Exploratory Dose-ranging to Investigate the Efficacy and Safety of 16 Weeks Treatment With Subcutaneous (s.c.) QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo and Active-controlled Study With Exploratory Dose-ranging to Investigate the Efficacy and Safety of 16 Weeks Treatment With Subcutaneous (s.c.) QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ligelizumab (Primary) ; Omalizumab
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 25 Apr 2016 Status changed from recruiting to completed.
    • 23 Apr 2016 This trial is completed in Germany (end date: 21 Jan 2016), according to European Clinical Trials Database record.
    • 21 Apr 2016 As per EudraCT record trial status is completed with end date 21 Jan 2016 in Finland, Slovakia, Czech Republic, Portugal, Hungary, Italy and Poland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top